Loading...
XCSE
PEG
Market cap14mUSD
Oct 07, Last price  
0.08DKK
1D
3.47%
1Q
-5.60%
IPO
-81.07%
Name

Pharma Equity Group A/S

Chart & performance

D1W1MN
XCSE:PEG chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
107.62%
Rev. gr., 5y
%
Revenues
0
00517,00015,486,00013,252,00049,367,000132,000620,0001,054,000000000000
Net income
-25m
L+3.93%
-92,669,000-12,036,000-1,415,000-16,978,000-43,279,000-141,827,000-5,930,000-2,773,000-1,035,000177,000-7,713,000-14,417,000-32,875,0005,392,0003,479,000-24,609,000-24,422,000-25,382,000
CFO
-18m
L-22.75%
0-744,000-17,747,000-5,713,000-10,559,000-5,789,000-4,800,000-2,938,000-181,000-4,921,000-1,579,000-274,000-9,905,000-2,089,000-2,874,000-16,624,000-22,861,000-17,661,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.

Key people

Peter Hauge Jensen
Chief Executive Officer · since 2019
Claus Abildstroem
Director · since 2017
Ulrik Feldstedt Hjorth
Director · since 2019
Rolf Gordon Adamson
Director · since 2019
URL
https://pharmaequitygroup.com/
IPO date
Jun 25, 2003
Employees
Domiciled in
DK
Incorporated in
DK
Headquarters & legal address
Slotsmarken 12, 1. th
Hørsholm, 84 2970
DK
Previous name
BLUE VISION A/S

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT